NO20025821L - 2-aminokarbonyl-9H-purinderivater - Google Patents

2-aminokarbonyl-9H-purinderivater

Info

Publication number
NO20025821L
NO20025821L NO20025821A NO20025821A NO20025821L NO 20025821 L NO20025821 L NO 20025821L NO 20025821 A NO20025821 A NO 20025821A NO 20025821 A NO20025821 A NO 20025821A NO 20025821 L NO20025821 L NO 20025821L
Authority
NO
Norway
Prior art keywords
aminocarbonyl
purine
preparation
compounds
solvates
Prior art date
Application number
NO20025821A
Other languages
English (en)
Other versions
NO324426B1 (no
NO20025821D0 (no
Inventor
Simon John Mantell
Peter Thomas Stephenson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014048A external-priority patent/GB0014048D0/en
Priority claimed from GB0024920A external-priority patent/GB0024920D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20025821D0 publication Critical patent/NO20025821D0/no
Publication of NO20025821L publication Critical patent/NO20025821L/no
Publication of NO324426B1 publication Critical patent/NO324426B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)

Abstract

Det er beskrevet forbindelser med formel (1) og farmasøytisk akseptable: salter og solvater derav, og fremgangsmåter for fremstilling derav, mellomprodukter anvendt i fremstillingen, sammensetninger som inneholder disse og anvendelse av slike forbindelser.
NO20025821A 2000-06-06 2002-12-04 2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning NO324426B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0014048A GB0014048D0 (en) 2000-06-06 2000-06-06 Purine derivatives
GB0018246A GB0018246D0 (en) 2000-06-06 2000-07-25 Purine derivatives
GB0024920A GB0024920D0 (en) 2000-06-06 2000-10-11 Purine derivatives
PCT/IB2001/000973 WO2001094368A1 (en) 2000-06-06 2001-06-05 2-aminocarbonyl-9h-purine derivatives

Publications (3)

Publication Number Publication Date
NO20025821D0 NO20025821D0 (no) 2002-12-04
NO20025821L true NO20025821L (no) 2003-02-04
NO324426B1 NO324426B1 (no) 2007-10-08

Family

ID=27255754

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025821A NO324426B1 (no) 2000-06-06 2002-12-04 2-aminokarbonyl-9H-purinderivater, samt anvendelse og fremgangsmate for fremstilling derav, og farmasoytisk sammensetning

Country Status (33)

Country Link
EP (1) EP1292604B1 (no)
JP (2) JP4129176B2 (no)
KR (1) KR100484704B1 (no)
CN (1) CN1249074C (no)
AR (1) AR030289A1 (no)
AT (1) ATE431356T1 (no)
AU (2) AU6053701A (no)
BG (1) BG107216A (no)
BR (1) BR0111263A (no)
CA (1) CA2414018C (no)
CU (1) CU23240B7 (no)
CZ (1) CZ20023875A3 (no)
DE (1) DE60138702D1 (no)
DK (1) DK1292604T3 (no)
DZ (1) DZ3439A1 (no)
EA (1) EA004983B1 (no)
EE (1) EE200200678A (no)
ES (1) ES2324816T3 (no)
GC (1) GC0000287A (no)
HR (1) HRP20020960A2 (no)
HU (1) HUP0301330A3 (no)
IL (2) IL152783A0 (no)
IS (1) IS6599A (no)
MA (1) MA26910A1 (no)
MX (1) MXPA02012033A (no)
NO (1) NO324426B1 (no)
NZ (1) NZ522184A (no)
OA (1) OA12279A (no)
PA (1) PA8518801A1 (no)
PL (1) PL360435A1 (no)
SK (1) SK16752002A3 (no)
TW (1) TWI227240B (no)
WO (1) WO2001094368A1 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
SG176313A1 (en) 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0129270D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Pharmaceutical combination
US6974803B2 (en) 2001-12-06 2005-12-13 Pfizer Inc Pharmaceutical combination
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
EP1496911B1 (en) * 2002-04-10 2007-12-19 University Of Virginia Patent Foundation Use of a combination comprising a2a adenosine receptor agonists and anti-pathogenic agents for the treatment of inflammatory diseases
WO2004080411A2 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
WO2004081005A1 (en) * 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005040174A1 (en) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
US7749980B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
CA2576826C (en) 2004-08-02 2014-09-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
JO3465B1 (ar) 2008-06-19 2020-07-05 Takeda Pharmaceuticals Co مركب متغاير الحلقه واستخدامه
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
AU2010252609A1 (en) 2009-05-29 2011-11-10 Pfizer Limited Novel glucocorticoid receptor agonists
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914526A (pt) * 1998-10-16 2001-07-03 Pfizer Derivados de adenina
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives

Also Published As

Publication number Publication date
EE200200678A (et) 2004-06-15
KR20030032962A (ko) 2003-04-26
IS6599A (is) 2002-10-29
CN1434830A (zh) 2003-08-06
JP2008150383A (ja) 2008-07-03
JP4129176B2 (ja) 2008-08-06
NO324426B1 (no) 2007-10-08
ES2324816T3 (es) 2009-08-17
ATE431356T1 (de) 2009-05-15
IL184144A (en) 2008-11-26
IL152783A0 (en) 2003-06-24
BG107216A (bg) 2003-05-30
NZ522184A (en) 2004-05-28
NO20025821D0 (no) 2002-12-04
PL360435A1 (en) 2004-09-06
KR100484704B1 (ko) 2005-04-22
CN1249074C (zh) 2006-04-05
HRP20020960A2 (en) 2005-02-28
AU2001260537B2 (en) 2006-05-25
SK16752002A3 (sk) 2004-05-04
CZ20023875A3 (cs) 2004-02-18
IL184144A0 (en) 2007-10-31
CA2414018A1 (en) 2001-12-13
GC0000287A (en) 2006-11-01
HUP0301330A3 (en) 2005-02-28
MA26910A1 (fr) 2004-12-20
CU23240B7 (es) 2007-10-17
HUP0301330A2 (hu) 2003-08-28
AR030289A1 (es) 2003-08-20
MXPA02012033A (es) 2003-04-25
DE60138702D1 (de) 2009-06-25
AU6053701A (en) 2001-12-17
OA12279A (en) 2003-01-01
TWI227240B (en) 2005-02-01
JP2003535871A (ja) 2003-12-02
HK1089447A1 (zh) 2006-12-01
CA2414018C (en) 2007-10-16
EA200201179A1 (ru) 2003-04-24
WO2001094368A1 (en) 2001-12-13
HK1054042A1 (en) 2003-11-14
BR0111263A (pt) 2003-06-17
PA8518801A1 (es) 2002-09-17
EP1292604B1 (en) 2009-05-13
EA004983B1 (ru) 2004-10-28
DZ3439A1 (fr) 2001-12-13
DK1292604T3 (da) 2009-06-15
EP1292604A1 (en) 2003-03-19

Similar Documents

Publication Publication Date Title
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
GB0124933D0 (en) Chemical compounds
IS6658A (is) Ný efnasambönd
DE60112974D1 (en) Carbolinderivate
IS6520A (is) Ný efnasambönd
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
ATE316083T1 (de) Adamantanderivate
MXPA02012076A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
MXPA03002911A (es) Compuestos quimicos.
NO996108L (no) 9-oksinerytromycinderivater
MXPA03009750A (es) Compuestos quimicos.
MXPA03007142A (es) Derivados de carbolina.
WO2002048148A3 (en) Pyrazolopyridine derivatives
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
SE0102055D0 (sv) New Compounds
SE0101038D0 (sv) Novel compounds
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2002213419A1 (en) Condensed pyridoindole derivatives
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
ATE274515T1 (de) Pyrazolopyridinderivate
NO20044466L (no) Plasma-karboksypeptidase B-inhibitorer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees